- Analyst Robert W. Baird reduced the price target for Oculis Holding AG (NASDAQ:OCS) to $38.00 from $49.00 following a significant clinical trial failure.
- The company’s lead drug candidate, OCS-01, failed to meet its primary endpoint in Phase 3 DIAMOND trials for diabetic macular edema.
- Despite this setback, Oculis Holding AG maintains a strong financial position with $278 million in cash and short-term investments, providing a “cash runway” into the second half of 2029 while the company reorients its drug development pipeline.
Oculis Holding AG (NASDAQ:OCS) is a leading biopharmaceutical company that develops innovative treatments for eye diseases. On June 1, 2026, an analyst at Robert W. Baird reduced their price target for Oculis to $38.00 from $49.00. A price target is an analyst’s projection of a stock’s future price, often used in stock analysis. At the time, the stock was trading at $14.51.
This price target adjustment follows a major setback for the company. The stock price for Oculis fell by approximately 23.4% in one day after its lead product, OCS-01, failed in late-stage clinical trials. The Phase 3 DIAMOND trials did not meet their primary goal of improving vision in patients with diabetic macular edema.
Due to the trial failure, Oculis has stopped its plans for a U.S. Food and Drug Administration (FDA) filing for OCS-01 for that condition, as highlighted by MarketBeat. The law firm Levi & Korsinsky has also started an investigation into the company over allegations that it may have misled investors about the trial’s progress.
Despite the outcome, Oculis noted that OCS-01 did show a “sustained reduction in retinal thickness,” a secondary goal of the study. Oculis will now shift its financial resources and focus, prioritizing its other drug development programs for conditions like optic neuropathies and dry eye disease.
The company reports a strong financial position, with $278 million in cash and short-term investments as of March 31, 2026. This provides a crucial “cash runway”, meaning Oculis has enough funds to support its operations into the second half of 2029, despite the recent clinical trial disappointment.
